Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Mazyar Shadman, Jeff P Sharman + Show 13 more

Open Access

https://doi.org/10.1182/blood-2020-134621

Copy DOI

Export

Save

Share

Cite

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 4

Affiliation: Fred Hutch Cancer Center, Willamette Valley Cancer Institute and Research Center, Texas Oncology, Medical Oncology Hematology Consultants, Florida Cancer Specialists & Research Institute, Summit Medical Group (United States), Rocky Mountain Cancer Centers, BeiGene (China), Tennessee Oncology, Sarah Cannon

#For-profit Health Care Company #Research Funding #Bruton Tyrosine Kinase ) Inhibitors #Equity Holder In Publicly-traded Company #Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma #Advisory Committees #Publicly-traded Company #Current Equity Holder #Speakers Bureau #Current Employment

Abstract
Full-Text
Similar Papers

Abstract

Phase 2 Study of Zanubrutinib in Patients with Relapsed/Refractory B-Cell Malignancies Intolerant to Ibrutinib/Acalabrutinib

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.